# SVIP

## Overview
SVIP (small VCP interacting protein) is a gene that encodes a small, coiled-coil protein involved in various cellular processes, particularly in the regulation of autophagy and lysosomal function. The SVIP protein interacts with the valosin-containing protein (VCP), also known as p97, which is crucial for membrane fusion and protein degradation pathways. This interaction is essential for recruiting VCP to lysosomes, thereby maintaining lysosomal integrity and facilitating the fusion of autophagosomes with lysosomes. SVIP's role in modulating autophagy is underscored by its influence on LC3 lipidation and p62 expression, which are critical for autophagic activity. The protein is highly expressed in the central nervous system, indicating its potential involvement in neuronal function and cellular homeostasis. Alterations in SVIP expression or mutations in the gene have been associated with neurodegenerative diseases and cancer, highlighting its clinical significance (Johnson2021SVIP; Nagahama2003SVIP; Wang2011SVIP).

## Structure
SVIP (small VCP interacting protein) is a small protein consisting of 76 amino acids in rats and 77 in humans, with an 82% sequence identity between the two species (Nagahama2003SVIP). The primary structure of SVIP includes a myristoylation site at Gly-2 and a palmitoylation site at Cys-4, which are potential sites for post-translational lipid modifications that may influence its membrane association (Nagahama2003SVIP). 

The secondary structure of SVIP is characterized by two putative coiled-coil regions located between residues 19-39 and 42-65, which are important for its interaction with VCP/p97 (Nagahama2003SVIP). These coiled-coil regions facilitate the binding of SVIP to the ND1 domain of VCP/p97, a critical interaction for its function (Nagahama2003SVIP).

SVIP does not exhibit significant sequence homology with other proteins, except for its interaction motif with VCP/p97, which is shared with other proteins like gp78 (Khodayari2017SVIP). The protein's tertiary and quaternary structures are not detailed in the available literature, and no splice variant isoforms have been specifically mentioned.

## Function
SVIP (small VCP interacting protein) is a critical co-factor for the valosin-containing protein (VCP), playing a significant role in lysosomal function and autophagy. In healthy human cells, SVIP is essential for recruiting VCP to lysosomes, which is crucial for maintaining the dynamic stability of the lysosomal network. This recruitment is vital for the fusion of autophagosomes with lysosomes, a key step in the autophagic process (Johnson2021SVIP; Wang2011SVIP).

SVIP modulates autophagy by influencing LC3 lipidation, a process necessary for the formation of autophagosomes. Knockdown of SVIP results in reduced LC3II levels, indicating decreased autophagic activity, while its overexpression enhances LC3 lipidation and autophagic degradation (Wang2011SVIP). SVIP also affects the levels of p62, a protein involved in autophagy, by promoting its expression and sequestration into autophagosomes (Wang2011SVIP).

SVIP is highly expressed in the central nervous system, particularly in the cerebrum and cerebellum, suggesting a role in neuronal function and cellular homeostasis (Wang2011SVIP). It also interacts with VCP in a mutually exclusive manner with other adaptors, indicating its unique role in modulating VCP's function in various cellular pathways (Nagahama2003SVIP).

## Clinical Significance
Mutations and alterations in the expression of the SVIP gene have been linked to several neurodegenerative diseases and cancer. In the context of neurodegenerative diseases, SVIP mutations can lead to conditions such as inclusion body myopathy with Paget's disease and frontotemporal dementia (IBMPFD), amyotrophic lateral sclerosis (ALS), and potentially Parkinson's disease. These mutations disrupt lysosomal dynamics and impair autophagosome-lysosome fusion, leading to muscle wasting and neuromuscular degeneration (Johnson2021SVIP). A specific SVIP mutation, p.S77L, identified in a cohort of frontotemporal dementia patients, disrupts lysosome structure and function, further linking SVIP to neurodegenerative conditions (Johnson2021SVIP).

In cancer, particularly glioblastoma, SVIP plays a role in tumor progression by interacting with PTEN and STUB1. SVIP stabilizes PTEN by inhibiting its degradation, thereby affecting the PI3K/AKT/mTOR signaling pathway. Reduced SVIP expression is associated with increased glioblastoma cell proliferation and migration, suggesting its potential as a therapeutic target (Wang2024SVIP).

SVIP also influences the degradation of misfolded proteins in conditions like alpha-1 antitrypsin deficiency (AATD). It inhibits the ubiquitin ligase gp78, affecting the ER-associated degradation pathway and leading to the accumulation of misfolded proteins, which can exacerbate AATD (Khodayari2017SVIP).

## Interactions
SVIP (small VCP interacting protein) is known to interact with the valosin-containing protein (VCP), also known as p97, which is involved in various cellular processes such as membrane fusion and protein degradation. SVIP binds to the N-terminal and ATP-binding regions of VCP, forming a distinct complex separate from other VCP-interacting proteins like p47 and Ufd1p. These interactions are mutually exclusive, meaning that SVIP, p47, and Ufd1p cannot bind to VCP simultaneously (Nagahama2003SVIP).

SVIP's interaction with VCP is crucial for recruiting VCP to lysosomes, which is essential for maintaining lysosomal integrity and function. This interaction is disrupted by specific mutations in the VCP-interaction motif (VIM) sequence of SVIP, leading to impaired lysosomal dynamics and autophagy (Johnson2021SVIP).

SVIP also influences the subcellular localization of VCP, causing it to relocate to the plasma membrane, intracellular foci, and juxtanuclear vacuoles. This relocalization is dependent on SVIP's myristoylation and VIM, and it plays a role in regulating autophagy by enhancing LC3 lipidation and p62 expression (Wang2011SVIP).


## References


[1. (Wang2011SVIP) Yang Wang, Petek Ballar, Yongwang Zhong, Xuebao Zhang, Chao Liu, Ying-Jiu Zhang, Mervyn J. Monteiro, Jun Li, and Shengyun Fang. Svip induces localization of p97/vcp to the plasma and lysosomal membranes and regulates autophagy. PLoS ONE, 6(8):e24478, August 2011. URL: http://dx.doi.org/10.1371/journal.pone.0024478, doi:10.1371/journal.pone.0024478. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0024478)

[2. (Khodayari2017SVIP) Nazli Khodayari, Rejean liqun Wang, George Marek, Karina Krotova, Mariana Kirst, Chen Liu, Farshid Rouhani, and Mark Brantly. Svip regulates z variant alpha-1 antitrypsin retro-translocation by inhibiting ubiquitin ligase gp78. PLOS ONE, 12(3):e0172983, March 2017. URL: http://dx.doi.org/10.1371/journal.pone.0172983, doi:10.1371/journal.pone.0172983. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0172983)

[3. (Nagahama2003SVIP) Masami Nagahama, Mie Suzuki, Yuko Hamada, Kiyotaka Hatsuzawa, Katsuko Tani, Akitsugu Yamamoto, and Mitsuo Tagaya. Svip is a novel vcp/p97-interacting protein whose expression causes cell vacuolation. Molecular Biology of the Cell, 14(1):262â€“273, January 2003. URL: http://dx.doi.org/10.1091/mbc.02-07-0115, doi:10.1091/mbc.02-07-0115. This article has 73 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1091/mbc.02-07-0115)

[4. (Johnson2021SVIP) Alyssa E. Johnson, Brian O. Orr, Richard D. Fetter, Armen J. Moughamian, Logan A. Primeaux, Ethan G. Geier, Jennifer S. Yokoyama, Bruce L. Miller, and Graeme W. Davis. Svip is a molecular determinant of lysosomal dynamic stability, neurodegeneration and lifespan. Nature Communications, January 2021. URL: http://dx.doi.org/10.1038/s41467-020-20796-8, doi:10.1038/s41467-020-20796-8. This article has 31 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-20796-8)

[5. (Wang2024SVIP) Zixuan Wang, Xiaolong Qiao, Yinan Chen, Nan Peng, Chaoshi Niu, Yang Wang, Cong Li, Zengchun Hu, Caihua Zhang, and Chuandong Cheng. Svip reduces igfbp-2 expression and inhibits glioblastoma progression via stabilizing pten. Cell Death Discovery, August 2024. URL: http://dx.doi.org/10.1038/s41420-024-02130-z, doi:10.1038/s41420-024-02130-z. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41420-024-02130-z)